Xin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xin Chen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Xing Zhong
Hubei Selenium and Human Health Institute, the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, People’s Republic of China
3 shared publications- Yuhua Lei
Cardiovascular Disease Center, The Central Hospital Of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China
3 shared publications Dan Luo
Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China; Hubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China; Hubei Provincial Key Lab of Selenium Resources and Bio Applications, Enshi, Hubei Province, China
2 shared publicationsLu Ye
Health Science Center, Hubei Minzu University, Enshi, Hubei, People’s Republic of China
2 shared publicationsPusong Tang
Health Science Center, Hubei Minzu University, Enshi, Hubei, People’s Republic of China
2 shared publications- Rui Huang
Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-18
A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome
Semaglutide (SEM), a GLP-1 receptor agonist (GLP-1RA), is commonly used to manage blood glucose and weight in type 2 diabetes mellituspatients (T2DM). Research indicates that SEM protects the kidneys and heart by slowing estimated glomerular filtration rate (eGFR) decline, reducing proteinuria, enhancing cardiac outcomes, and lowering cardiovascular risk. These benefits are linked to various mechanisms, including reduced oxidative stress and inflammation, anti-fibrotic effects, modulation of metabolism, inhibition of apoptosis, suppression of ferroptosis, and improved mitochondrial function for energy regulation. However, some studies have also found that SEM may potentially lead to renal impairment or even promote the progression of cardiorenal syndrome (CRS). Due to conflicting results, more animal studies and large-scale clinical trials are needed to understand SEM’s effects on CRS and its side effects, aiding in personalized treatment strategies. This review summarizes the functions and mechanisms of SEM in CRS, and highlights current research limitations and proposed directions for future studies.
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-18
Open AccessA Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome
Semaglutide (SEM), a GLP-1 receptor agonist (GLP-1RA), is commonly used to manage blood glucose and weight in type 2 diabetes mellituspatients (T2DM). Research indicates that SEM protects the kidneys and heart by slowing estimated glomerular filtration rate (eGFR) decline, reducing proteinuria, enhancing cardiac outcomes, and lowering cardiovascular risk. These benefits are linked to various mechanisms, including reduced oxidative stress and inflammation, anti-fibrotic effects, modulation of metabolism, inhibition of apoptosis, suppression of ferroptosis, and improved mitochondrial function for energy regulation. However, some studies have also found that SEM may potentially lead to renal impairment or even promote the progression of cardiorenal syndrome (CRS). Due to conflicting results, more animal studies and large-scale clinical trials are needed to understand SEM’s effects on CRS and its side effects, aiding in personalized treatment strategies. This review summarizes the functions and mechanisms of SEM in CRS, and highlights current research limitations and proposed directions for future studies.
- Open Access
- 22 October 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 180, 117560
Fraxinellone protects against cardiac injury and decreases ventricular fibrillation susceptibility during myocardial ischemia-reperfusion
- 22 October 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 180, 117560
Open AccessFraxinellone protects against cardiac injury and decreases ventricular fibrillation susceptibility during myocardial ischemia-reperfusion
- Open Access
- 1 April 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 1651-1664
Plasma SMOC2 Predicts Prognosis in Patients with Heart Failure: A Prospective Cohort
Background: Heart failure (HF) is a chronic disease with a poor prognosis, making it extremely important to assess the prognosis of patients with HF for accurate treatment. Secreted modular calcium-binding protein 2 (SMOC2) is a cysteine-rich acidic secreted protein that plays a pathophysiological role in many diseases, including regulation of vascular growth factor activity. It has previously been found that SMOC2 plays an essential role in cardiac fibrosis in our previous preclinical study, but whether it can be used as a clinical marker in heart failure patients remains unclear. The purpose of this research was to evaluate the correlation between plasma levels of SMOC2 and the prognosis for individuals with HF. Methods: HF patients diagnosed with ischemic cardiomyopathy were enrolled from January to December 2021. Baseline plasma levels of SMOC2 were measured after demographic and clinical features were collected. Linear and nonlinear multivariate Cox regression models were used to determine the association between plasma SMOC2 and patient outcomes during follow-up. All analysis was performed using SPSS, EmpowerStats, and R software. Results: The study included 188 patients, and the average follow-up time was 489.5± 88.3 days. The plasma SMOC2 concentrations were positively correlated with N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), left ventricular end-diastolic diameter (LVEDd), and length of hospital stay and were negatively correlated with left ventricular ejection fraction (LVEF) at baseline. A total of 53 patients (28.2%) were rehospitalized due to cardiac deterioration, 14 (7.4%) died, and 37 (19.7%) developed malignant arrhythmias. A fully adjusted multivariate COX regression model showed that SMOC2 is associated with readmission (HR = 1.02, 95% CI:1.012– 1.655). A significant increase in rehospitalization risk was observed in group Q2 (HR =1.064, 95% CI: 1.037, 3.662, p=0.005) and group Q3 (HR =1.085, 95% CI:1.086, 3.792, p=0.009) in comparison with group Q1. The p for trend also shows a linear correlation across the three models (P < 0.001). SMOC2 was associated with the severity of HF in patients, but not with all-cause deaths and arrhythmias during follow-up. Conclusion: Plasma SMOC2 is associated with the severity of HF and readmission rate, and is a good predictor of the risk of readmission in patients.
- 1 April 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 1651-1664
Open AccessPlasma SMOC2 Predicts Prognosis in Patients with Heart Failure: A Prospective Cohort
Background: Heart failure (HF) is a chronic disease with a poor prognosis, making it extremely important to assess the prognosis of patients with HF for accurate treatment. Secreted modular calcium-binding protein 2 (SMOC2) is a cysteine-rich acidic secreted protein that plays a pathophysiological role in many diseases, including regulation of vascular growth factor activity. It has previously been found that SMOC2 plays an essential role in cardiac fibrosis in our previous preclinical study, but whether it can be used as a clinical marker in heart failure patients remains unclear. The purpose of this research was to evaluate the correlation between plasma levels of SMOC2 and the prognosis for individuals with HF. Methods: HF patients diagnosed with ischemic cardiomyopathy were enrolled from January to December 2021. Baseline plasma levels of SMOC2 were measured after demographic and clinical features were collected. Linear and nonlinear multivariate Cox regression models were used to determine the association between plasma SMOC2 and patient outcomes during follow-up. All analysis was performed using SPSS, EmpowerStats, and R software. Results: The study included 188 patients, and the average follow-up time was 489.5± 88.3 days. The plasma SMOC2 concentrations were positively correlated with N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), left ventricular end-diastolic diameter (LVEDd), and length of hospital stay and were negatively correlated with left ventricular ejection fraction (LVEF) at baseline. A total of 53 patients (28.2%) were rehospitalized due to cardiac deterioration, 14 (7.4%) died, and 37 (19.7%) developed malignant arrhythmias. A fully adjusted multivariate COX regression model showed that SMOC2 is associated with readmission (HR = 1.02, 95% CI:1.012– 1.655). A significant increase in rehospitalization risk was observed in group Q2 (HR =1.064, 95% CI: 1.037, 3.662, p=0.005) and group Q3 (HR =1.085, 95% CI:1.086, 3.792, p=0.009) in comparison with group Q1. The p for trend also shows a linear correlation across the three models (P < 0.001). SMOC2 was associated with the severity of HF in patients, but not with all-cause deaths and arrhythmias during follow-up. Conclusion: Plasma SMOC2 is associated with the severity of HF and readmission rate, and is a good predictor of the risk of readmission in patients.
- Open Access
- 1 December 2023
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 17, 3833-3843
A Review on the Pharmacological Aspects of Engeletin as Natural Compound
Background: Engeletin (ENG) is a natural flavonoid compound known for its diverse physiological and pharmacological effects, such as anti-inflammatory, antioxidant, and immunomodulatory properties. It has garnered significant attention as a promising candidate for drug development. Objective: This article aims to comprehensively review the clinical application, pharmacological action, and potential mechanisms of ENG, while exploring its prospects in clinical pharmacology. Methods: We conducted a systematic search of PubMed, Science Direct, Google Scholar, Web of Science, Scopus, and MEDLINE for a thorough review of high-quality articles on the source, extraction, and application of ENG, or the primary active ingredient for improving bodily injuries. Results: ENG exhibits significant potential in treating a variety of diseases across different systems, attributed to its anti-inflammatory, antioxidant, anti-tumor, and metabolic regulatory activities. These effects are linked to direct or indirect interactions with multiple pathways involving key molecules upstream and downstream. Conclusion: While ENG shows promise, its development requires further exploration. Future studies should focus on elucidating its mechanisms of action, identifying targets through clinical studies, and optimizing compounds for drug development. These research directions are crucial for advancing the development and application of flavonoids. This review underscores the significant research potential of ENG, paving the way for its application in diverse clinical settings.
- 1 December 2023
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 17, 3833-3843
Open AccessA Review on the Pharmacological Aspects of Engeletin as Natural Compound
Background: Engeletin (ENG) is a natural flavonoid compound known for its diverse physiological and pharmacological effects, such as anti-inflammatory, antioxidant, and immunomodulatory properties. It has garnered significant attention as a promising candidate for drug development. Objective: This article aims to comprehensively review the clinical application, pharmacological action, and potential mechanisms of ENG, while exploring its prospects in clinical pharmacology. Methods: We conducted a systematic search of PubMed, Science Direct, Google Scholar, Web of Science, Scopus, and MEDLINE for a thorough review of high-quality articles on the source, extraction, and application of ENG, or the primary active ingredient for improving bodily injuries. Results: ENG exhibits significant potential in treating a variety of diseases across different systems, attributed to its anti-inflammatory, antioxidant, anti-tumor, and metabolic regulatory activities. These effects are linked to direct or indirect interactions with multiple pathways involving key molecules upstream and downstream. Conclusion: While ENG shows promise, its development requires further exploration. Future studies should focus on elucidating its mechanisms of action, identifying targets through clinical studies, and optimizing compounds for drug development. These research directions are crucial for advancing the development and application of flavonoids. This review underscores the significant research potential of ENG, paving the way for its application in diverse clinical settings.
- Open Access
- 3 April 2020
- Published by Springer Nature in Research Square
Clinical characteristics of 208 patients with COVID-19 in a surrounding city of Wuhan, China
Background: Since December 2019, a severe novel coronavirus (SARS-CoV-2) infection (Coronavirus Disease 2019,COVID-19) has occurred in Wuhan, China, and has rapidly spread to the country and around the world. This study intends to investigate the epidemiological and clinical characteristics of patients with COVID-19 in a surrounding city of Wuhan.Methods: A retrospective study was conducted on 208 cases of COVID -19 patients from February 11, 2020 to February 29, 2020 in Xiaogan dongnan Hospital, collected basic information, history of exposure, medical history, clinical symptoms, laboratory indicators and pulmonary imaging Data, and analyzed the epidemiological and clinical characteristics of all patients. According to the clinical classification criteria, 208 patients were divided into light group and ordinary group, and the epidemiological and clinical characteristics of the two groups were compared.Results: Among 208 patients in this study, with a median age of 50.5 years (IQR,36-64.7,range,10-91 years), among which 107 (51.4%) were males and 101 (48.6%) were females. 51 (24.5%) had a clear exposure to COVID-19 infection within 2 weeks before admission, and 40 (19.2%) had a history of residence or exposure in Wuhan within 2 weeks before admission. Among all the patients, there were 16 (7.7%) with pulmonary diseases, 41 (19.7%) with hypertension, 11 (5.3%) with coronary heart disease, 13 (6.3%) with diabetes, 12(5.8%) with a history of alcohol consumption, and 12(5.8%) with a history of smoking. Among all clinical symptoms, 146 cases (70.2%) of fever, the highest temperature range was 37.3℃-41℃ before admission, 115 (55.3%) cases of cough, and 57 (27.4%) cases of chest tightness, 47 (22.6%) cases of fatigue, 28 (13.5%) cases of inappetence, 9 (4.3%) cases of diarrhea, 7 (3.4%) cases of nasal congestion or runny nose , and 5 ( 2.4%) cases of pharyngalgia. Analysis of the laboratory results of 208 patients showed that 42 (20.2%) cases had decreased white blood cell count, and 61 (29.3%) cases had decreased lymphocyte count. There were 154 (74%) cases with elevated CRP, 50 (24%) cases with elevated fasting blood glucose, and 23 (11.1%) cases with elevated LDH (>245U/L). The comparison of clinical characteristics between the light group and the common group showed that the median age of the light group was 44.8 years (IQR 30-58), the median age of the common group was 53.1 years (IQR 38.8-67) (PConclusion: COVID-19 infection is mainly in middle-aged and elderly patients, patients with other diseases are more susceptible to infection. The main symptoms of COVID-19 infection were fever, cough, chest tightness, fatigue, and inappetence. Decreased lymphocyte count, increased CRP concentration, increased LDH concentration and decreased HDL-C concentration were the laboratory features of COVID-19 infection, and were important indicators to assess the severity of COVID-19 disease.
- 3 April 2020
- Published by Springer Nature in Research Square
Open AccessClinical characteristics of 208 patients with COVID-19 in a surrounding city of Wuhan, China
Background: Since December 2019, a severe novel coronavirus (SARS-CoV-2) infection (Coronavirus Disease 2019,COVID-19) has occurred in Wuhan, China, and has rapidly spread to the country and around the world. This study intends to investigate the epidemiological and clinical characteristics of patients with COVID-19 in a surrounding city of Wuhan.Methods: A retrospective study was conducted on 208 cases of COVID -19 patients from February 11, 2020 to February 29, 2020 in Xiaogan dongnan Hospital, collected basic information, history of exposure, medical history, clinical symptoms, laboratory indicators and pulmonary imaging Data, and analyzed the epidemiological and clinical characteristics of all patients. According to the clinical classification criteria, 208 patients were divided into light group and ordinary group, and the epidemiological and clinical characteristics of the two groups were compared.Results: Among 208 patients in this study, with a median age of 50.5 years (IQR,36-64.7,range,10-91 years), among which 107 (51.4%) were males and 101 (48.6%) were females. 51 (24.5%) had a clear exposure to COVID-19 infection within 2 weeks before admission, and 40 (19.2%) had a history of residence or exposure in Wuhan within 2 weeks before admission. Among all the patients, there were 16 (7.7%) with pulmonary diseases, 41 (19.7%) with hypertension, 11 (5.3%) with coronary heart disease, 13 (6.3%) with diabetes, 12(5.8%) with a history of alcohol consumption, and 12(5.8%) with a history of smoking. Among all clinical symptoms, 146 cases (70.2%) of fever, the highest temperature range was 37.3℃-41℃ before admission, 115 (55.3%) cases of cough, and 57 (27.4%) cases of chest tightness, 47 (22.6%) cases of fatigue, 28 (13.5%) cases of inappetence, 9 (4.3%) cases of diarrhea, 7 (3.4%) cases of nasal congestion or runny nose , and 5 ( 2.4%) cases of pharyngalgia. Analysis of the laboratory results of 208 patients showed that 42 (20.2%) cases had decreased white blood cell count, and 61 (29.3%) cases had decreased lymphocyte count. There were 154 (74%) cases with elevated CRP, 50 (24%) cases with elevated fasting blood glucose, and 23 (11.1%) cases with elevated LDH (>245U/L). The comparison of clinical characteristics between the light group and the common group showed that the median age of the light group was 44.8 years (IQR 30-58), the median age of the common group was 53.1 years (IQR 38.8-67) (PConclusion: COVID-19 infection is mainly in middle-aged and elderly patients, patients with other diseases are more susceptible to infection. The main symptoms of COVID-19 infection were fever, cough, chest tightness, fatigue, and inappetence. Decreased lymphocyte count, increased CRP concentration, increased LDH concentration and decreased HDL-C concentration were the laboratory features of COVID-19 infection, and were important indicators to assess the severity of COVID-19 disease.